FARE - Food Allergy Research & Education Logo

Biomarkers in Food Allergy Diagnosis

Study Purpose

Food allergy is a global burden, affecting patients, society as a whole and the economy. For most common food allergies, patients synthesize specific IgE-antibodies against harmless food proteins. Clinical phenotypes of food-allergic patients are highly diverse. Differences in medical symptoms (organs, severity, delay), threshold and cross-reactivity levels suggest variable underlying endotypes. The aim of this study is to identify phenotypic biomarkers for advanced stratification of food-allergic patients. Our study will consist of up to 50 participants (30 food-allergic, 20 tolerant), recruited in Luxembourg. Clinical samples will be collected before, during and after the event of a double-blind placebo-controlled food challenge for patients. Multi-omics analyses of blood (sera, peripheral blood mononuclear cell, basophils) and stool will allow a deeper understanding of the underlying immune mechanisms, including allergen metabolism aspects, as well as the functional gut microbiome. Deciphering these basic aspects during the present pilot study is expected to pave the way towards novel personalized medicine approaches for diagnosing and treating of food-allergic individuals. This study is a cooperation project between the Centre Hospitalier de Luxembourg (CHL), the Luxemburg Institute of Health (LIH), the University of Luxembourg and the Integrated Biobank of Luxemburg (IBBL).

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

Yes
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Observational [Patient Registry]
Eligible Ages 2 Years - 70 Years
Gender All
More Inclusion & Exclusion Criteria

For the allergic cohort :

Inclusion criteria:

  • - 2-70 years.
  • - male or female.
  • - Allergic to peanut (assessed by anamnesis, skinreactivity testing, sera testing for specific IgE) - Sign an Informed Consent.
  • - Diagnostic food challenge scheduled.

Exclusion criteria:

  • - Significant co-morbidity.
  • - Medical treatment by nonsteroidal anti-inflammatory drugs oraspirin, chronic treatment with beta-blockers,angiotensin-converting enzyme inhibitors, use ofantihistamines within 5 days of oral food challenge and oral corticosteroids within 14 days prior to the challenge.
  • - Medical unfit for challenge (e.
g : fever,unwell with intercurrent illness)
  • - Pregant women.
  • - Unbalanced asthma.
  • - Severe food-induced anaphylaxis.
For the control cohort :

Inclusion criteria:

  • - Adults.
  • - male or female.
  • - Sign an Informed Consent.
  • - Tolerance to peanuts and fish (IgE-titer < 0.10 kUA/L) Exclusion criteria.
  • - Pregnancy.
  • - Medical unfit for challenge (e.
g : fever, unwell with intercurrent illness),
  • - Unbalanced asthma.
  • - Treatment by nonsteroidal anti-inflammatory drugs or aspirin.
  • - Chronic treatment with beta-blockers, angiotensin-converting enzyme inhibitors.
  • - Use of antihistamines within 5 days of oral food challenge.
  • - Oral corticosteroids within 14 days prior to the challenge.
- Risk of severe food-induced anaphylaxis in highly sensitized peanut-allergic patients

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT04604912
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Luxembourg Institute of Health
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Annette Kuehn, PhD
Principal Investigator Affiliation Luxembourg Institute of Health
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

OtherOtherOtherOtherOtherOther
Overall Status Recruiting
Countries Luxembourg
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Allergy;Food
Additional Details

Background. Food allergies are a global burden causing severe clinical reactions including fatal anaphylaxis. Peanuts are counted among the most potent elicitors involved in IgE-mediated food allergies. Peanut allergy is a relevant disease model because of its steadily increasing prevalence and poor prognosis of outgrowth. Clinical phenotypes of peanut-allergic patients are highly variable. Patients might experience variable medical symptoms (organs, severity, delay), threshold and cross-reactivity levels suggest. Reliable in-vitro biomarker allowing to predict clinical reactivity and score the patients into reaction endotypes are missing. Most important peanut allergens have been studied as to their biomolecular properties biological activities and allergenic potency. The pronounced protein stability of potent peanut allergens is thought to contribute to the molecules' allergenicity. Upon ingestion, food proteins are broken down, entering the human body via epithelial surfaces. The identity and the fate of immunologically active allergen peptides after epithelial absorption remains elusive. Beyond this, complex immune cascades take place during acute allergic episodes. How immune cells, such as lymphocytes, orchestrate in patients with different clinical outcomes (e.g., sensitivity, severity) still remains to be solved. Several studies have shown that the composition and the diversity of the gut microbiota is relevant for shaping the immune response to food proteins. The functional interaction between host and gut microbiome, in the context of symptom development and phenotypic variations, is unexplored until today. Aims. This project aims to explore putative biomarkers at various levels, at the level of IgE-profiles, at the level of allergen absorption, at the level of scored basophil reactivity, at the level of immune phenotypes and at the level of gut microbiome-host interactions, by applying multiple omics technologies. Partners. The Luxembourg Institute of Health (LIH), Department of Infection and Immunity (DII; head Prof. M. Ollert) has the scientific project lead (Principal Investigator Dr. A. Kuehn). Main clinical partners are Dr. F. Codreanu-Morel from the National Unit of Immunology-Allergology, Centre Hospitalier (CHL), Luxembourg, as well as Prof. C. Bindslev-Jensen from Odense Research Centre for Anaphylaxis (ORCA), Denmark. Partner for the execution of the clinical part will be the Clinical and Epidemiological Investigation Center (CIEC, LIH) headed by Dr. M. Gantenbein. The Integrated Biobank of Luxembourg (IBBL) will prepare and store clinical samples until use. Clinical samples (blood, sera, plasma) will be analyzed at DII, LIH. Stool samples will be investigated with the help of Prof. P. Wilmes from the Systems Ecology research group, Luxembourg Centre for Systems Biomedicine (LCSB). Project implementation. Food challenges (OFC) to peanut will be proceeded according to official guidelines (European Academy of Allergy and Clinical Immunology, EAACI). Healthy controls (N=10) will be split, half will receive a single food dose of up to 100 g of roasted peanuts (open OFC) and the other half will be tested with up to 5 incremental doses (double-blind placebo-controlled OFC) using the same doses as for allergic patients. For single-dose OFC, blood samples from controls will be taken before the OFC and at 30 minutes, at 60 minutes and at 120 minutes. Controls receiving 5 incremental allergen doses will be subjected to blood sampling before the beginning of the OFC and 1 h after the end of the challenge. As a further control arm in the study, allergenic food from animal origin will be used in OFC. Further healthy controls (N=10) will receive either a single food dose of up to 200 g of cooked fish (open OFC) and the other half will be tested with up to 5 incremental doses (double-blind placebo-controlled OFC). Doses in a range of 10 mg to 100 g of fish will be selected for the blinded OFC with controls. Allergic participants (N=30) will ingest incremental doses of peanuts. The OFC doses will be in the range of 5 mg, 15 mg, 60 mg, 120 mg, 200 mg, 390 mg, 790 mg, 1,580 mg, 3,160 mg and 5,530 mg of roasted peanut. Maximum five doses will be selected from the above mentioned ranges of peanut doses. Upon observation of allergic symptoms, the OFC will be stopped. If no allergic symptoms occurred during a food challenge with five incremental doses, the patient will be asked to participate in a second oral provocation (min. 14 days later) in order to undergo a test with higher allergen doses. Blood samples from allergic study participants will be drawn prior, during and after OFC (0, 60, 150, 180 minutes). Stool samples from peanut-allergic participants (n=30) and healthy controls (n=20) will be collected earliest 2 months after the food challenge. Prior sampling, participants should not have used antibiotics within the last month, or have recent/ongoing gastrointestinal symptoms (= diarrhea; Bristol scale 5-7) at the time of stool collection. Participants will receive a collection kit at home, containing special sampling tubes, gloves and instructions. In addition, patients are asked to record their food intake for the last 24 hours before sampling. Collected clinical samples will be pseudonymized at the clinical centers. A synonym list, as part of the investigator file, containing the information on the participants' identity and the corresponding pseudonym, will be available at the clinical center only (medical investigators) and at CIEC. Personal data is protected under the regulation (EU) 2016/679 of 27 April 2016 on the protection of individuals with regard to the processing of personal data (GDPR) and the law of 1 August 2018 on the organization of the National Data Protection Commission and the General Data Protection Act.

Arms & Interventions

Arms

: Peanut-allergic patients' group

The aim is to include 30 patients with peanut allergy. Those patients will undergo diagnostic food challenges (incremental doses) while blood will be samples before, during and after the testing. The patients will receive standard of care during and after the challenge. Allergic symptoms will be treated according to established guidelines.

: Control group

The aim is to include 20 control participants, 10 peanut-tolerant and 10 fish-tolerant individuals. Those participants will undergo diagnostic food challenges (incremental or single doses) while blood will be samples before, during and after the testing. Same safety measures will be applied for food challenges of control individuals, as for the allergic patients.

Interventions

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg

Status

Active, not recruiting

Address

Luxembourg Institute of Health

Esch-sur-Alzette, , 4354

Centre Hospitalier Luxembourg, Luxembourg, Luxembourg

Status

Recruiting

Address

Centre Hospitalier Luxembourg

Luxembourg, , 1210

Site Contact

Francoise Morel, MD

Morel.Francoise@chl.lu

+352 4411-6544

The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation.